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The complement system is a family of more 
than 30 proteins and cell surface receptors that 
recognize pathogen-associated molecular pat-
terns, altered-self ligands, or immune com-
plexes. Complement activation through the 
classical, lectin, and alternative pathways induces 
several protective functions including direct 
pathogen opsonization and/or lysis, and en-
hancement of B and T responses (1). Through 
these innate and adaptive responses complement 
contributes to the development of immunity 
against some enveloped DNA and RNA viruses 
(2–5). Several of these viruses have been shown 
to trigger distinct pathways of complement acti-
vation in vitro. Glycoproteins of murine leu-
kemia, HIV, and human T cell lymphotropic 
viruses directly interact with C1q to activate the 
classical pathway (6). Carbohydrates on the 
structural proteins of HSV, hepatitis B, and in-
fl   uenza viruses bind mannose binding lectins 
(MBLs) and activate the lectin pathway (7, 8). 
Multiple viruses activate the alternative path-
way, including Sindbis (9), Sendai (10), measles 
(11, 12), and Epstein Barr viruses (13). How-
ever, the in vivo contribution of each comple-
ment activation pathway to the development of 
antiviral immunity has yet to be defi  ned.
West Nile encephalitis virus (WNV) is a 
single-stranded positive sense RNA virus of 
the Flaviviridae family. WNV cycles in nature 
between mosquitoes and birds, but also infects 
human, horses, and other vertebrates. The virus 
is endemic in parts of Africa, Asia, Europe, and 
the Middle East, and has become established in 
North America. Infected humans generally de-
velop a febrile illness, with a subset progressing 
to severe neurological disease. The elderly and 
patients with impaired immune systems are at 
greatest risk for the severe neurological mani-
festations of disease. Experiments in mice have 
begun to elucidate how an impaired host im-
mune response results in severe WNV infec-
tion. An intact innate and adaptive immune 
response is required to limit central nervous 
system (CNS) infection as mice defi  cient  in 
type I IFN, γδ T cells, B cells, soluble IgM, 
and CD8+ T cells are all highly susceptible to 
lethal infection (14–19). Additionally, comple-
ment is required to control WNV, as mice 
  defi  cient in either complement (C)3 or com-
plement receptor (CR)1/2 were vulnerable to 
lethal WNV infection (20).
In this study, we investigated the activa-
tion requirements  for  complement-mediated 
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control of WNV dissemination and disease. We observed a 
marked increased in WNV susceptibility in mice defi  cient in 
any of the pathways of complement activation. However, the 
virologic and immunologic phenotypes of the various com-
plement-defi   cient mice were distinct, suggesting that the 
concerted activation of the classical, lectin, and alternative 
pathways is required to fully prime adaptive immune re-
sponses and control WNV infection.
RESULTS
Complement activation in vivo after WNV infection
Previous studies have suggested that other pathogenic fl  avi-
viruses, such as Dengue virus, activate complement leading 
to consumption of complement proteins and more severe 
disease (21, 22). To confi  rm that complement activation oc-
curs in vivo after WNV infection, we compared the levels of 
functional C3 and C4 in the serum of naive and WNV-
  infected C57BL/6 mice using an erythrocyte hemolysis assay 
(Fig. 1 A). On day 2 after WNV infection, a time point at 
which peak viremia was observed (see Fig. 3 A), a 2.5-fold 
decrease in C3 functional activity (P < 0.0001) was measured. 
Signifi  cant decreases, albeit smaller, were also noted on days 
4 and 6 after infection (P ≤ 0.02). C4 activity (23) was also 
reduced at day 2 after WNV infection (Fig. 1 B). As the 
  catabolism of C3 in vivo generates a C3dg fragment, Western 
blot analysis was performed on serum from WNV-infected 
mice with an anti-C3 antibody. Increased levels of the 38-kD 
C3dg fragment were observed in serum at day 2 after WNV 
infection (Fig. 1 C); the identity of this fragment was 
  confi   rmed by its absence from serum of congenic C3-
  defi   cient mice. Collectively, our experiments suggest that 
WNV infection activates and consumes complement within 
days of infection.
Susceptibility of complement-defi  cient mice 
to WNV infection
To assess the mechanism of complement-mediated protec-
tion from WNV disease and the function of the classical, clas-
sical and lectin, or alternative pathways of complement 
activation in control of WNV, we evaluated morbidity and 
mortality in wild-type and congenic C1q−/−, C4−/−, factor D 
(fD)−/−, and factor B (fB)−/− C57BL/6 mice. Mice in all 
groups exhibited clinical signs of infection including weight 
loss, hunching, fur ruffl   ing, and decreased activity. However, 
mice defi  cient in any individual complement activation path-
way were more vulnerable to infection and had higher mor-
tality rates compared with wild-type mice (Fig. 2). Whereas 
only 35% of wild-type C57BL/6 mice succumbed to infec-
tion, 83% of C1q−/− (n = 60, P < 0.0001), 100% of C4−/− 
(n = 38, P < 0.0001), 74% of fD−/−, (n = 57, P = 0.0004), 
and 96% of fB−/− (n = 51, P < 0.0001) mice died after 
WNV infection (Fig. 2). Not all complement defi  ciencies 
were associated with enhanced susceptibility as infection of 
mice defi  cient in the C5a receptor (C5aR) survived at rates 
similar to wild-type mice (n = 50, P = 0.5). Although both 
fB and fD are components of the alternative pathway, a defi  -
ciency of fB caused greater mortality after WNV infection 
(P < 0.0001), possibly caused by residual alternative pathway 
activation in fD−/− mice (24). Overall, the C4−/− and fB−/− 
mice were more susceptible to lethal WNV infection than 
either C1q−/− or fD−/− mice (P < 0.0001). The increased 
susceptibility of fB−/− mice was also refl  ected by a decrease 
in the mean time to death from 10.9 ± 0.3 d for wild-type 
mice to 9.7 ± 0.1 d for the fB−/− mice (P = 0.002). No sta-
tistically signifi  cant decrease in the mean time to death was 
observed for C4−/− (10.3 ± 0.2 d), C1q−/− (11.7 ± 0.2 d), 
or fD−/− (11.0 ± 0.2 d) mice. Thus, defi  ciencies in all com-
plement activation pathways resulted in increased mortality 
after WNV infection. The most severe phenotypes were ob-
served in mice that had a combined defi  ciency in the classical 
and lectin pathways (C4−/−) or a complete defi  ciency in the 
alternative pathway (fB−/−).
WNV tissue burden in complement-defi  cient mice
To elucidate the mechanisms by which defi  ciencies in com-
plement activation pathways enhanced susceptibility to WNV 
infection, a kinetic analysis of viral burden was performed 
(Fig. 3 and 4). Wild-type and complement-defi  cient C57BL/6 
Figure 1.  Complement is activated in vivo in response to WNV 
infection. Levels of functional (A) C3 and (B) C4 were determined by 
erythrocyte hemolysis assay of serum samples from naive and WNV-
infected mice. Differences in the C3 and C4 activity between naive and 
WNV-infected mice were statistically signifi  cant (P < 0.05). (C) Serum 
complement activation was evaluated by Western blot using equal vol-
umes of serum (20 μl of 1/50 dilution) from naive wild-type and C3−/− 
mice and WNV-infected (day 2) wild-type mice. Bands corresponding to 
the C3 α chain (100 kD), C3 β chain (75 kD), and C3dg (38 kD) are labeled.JEM VOL. 203, May 15, 2006  1373
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mice were infected with WNV, and viral loads in the serum, 
spleen, inguinal lymph node, spinal cord, and brain were de-
termined on days 2, 4, 6, 8, and 10 after infection.
Viremia. Throughout the time course of infection, viremia 
was below the limit of detection by direct plaque assay in all 
samples (unpublished data). However, when viral RNA was 
measured by quantitative RT-PCR assay (25), additional in-
formation was obtained. In wild-type mice, viremia peaked 
at day 2 after infection and decreased over the next several 
days. No signifi  cant diff  erence in viremia was observed at any 
time point after infection in C1q−/−, fB−/−, or fD−/− mice 
(Fig. 3 A, P ≥ 0.5). The only variation among complement-
defi  cient mice occurred in C4−/− mice, which had slightly 
higher WNV RNA levels than wild-type mice (n = 8, P = 
0.009), but only on day 4 after infection.
Spleen and lymph node. Previous experiments have 
shown that a defi  ciency of C3 results in a delayed clearance 
of WNV from the spleen (20). To assess which complement 
pathway contributed to viral clearance in the spleen, we eval-
uated WNV burden in C1q−/−, C4−/−, fD−/−, and fB−/− 
mice (Fig. 3 B). Compared with wild-type mice, we ob-
served a slight delay in clearance of WNV from the spleen in 
a subset of fD−/− and fB−/− mice. At day 6 after infection, 
58% (7 of 12) and 73% (11 of 15) of fD−/− and fB−/− mice, 
respectively, had detectable infectious WNV in the spleen, 
whereas only 33% (5 of 15) of wild-type mice had infectious 
virus at this time point. On day 8 after infection 57% (8 of 14) 
of fB−/− mice still had measurable infectious virus in the 
spleen, whereas it was no longer detectable in wild-type 
mice. Surprisingly, infectious virus was never recovered from 
the spleens of C1q−/− mice at any point during the time 
course (n ≥ 11 for each time point). Consistent with this, at 
the peak of viral replication in the spleen, 120,000-fold lower 
levels of WNV RNA were detected by quantitative RT-
PCR from the spleens of C1q−/− mice compared with wild-
type mice (Fig. 3 C, P = 0.002). The peak viral burden and 
number of positive samples in the spleen also was signifi  cantly 
lower in the absence of C4 (P = 0.04). Whereas 80% (12 of 15) 
of wild-type spleen samples were positive for infectious virus 
at day 4 after infection, only 30% (4 of 12) from C4−/− mice 
had infectious virus. Moreover, on day 6 after infection 
60,000-fold lower levels of WNV RNA were detected in 
spleens of C4−/− mice (P = 0.001). Thus, in the spleen, clas-
sical pathway activation appears to be necessary for produc-
tive infection, whereas the alternative pathway contributes in 
part to its rapid clearance of WNV.
Decreased WNV burden in spleens of C1q−/− and C4−/− 
mice was not predicted. Previous studies in mice indicated 
that F4/80+ macrophages and CD19+ B cells were the prin-
cipal cellular targets for WNV infection in the spleen (18). 
Because infection of C1q−/− mice resulted in normal vire-
mia, we hypothesized that virus must replicate in another 
  peripheral tissue. Studies from our group and others (14, 26) 
indicate that draining lymph nodes are an early site of WNV 
replication. To determine one possible source of viremia in 
Figure 2.  All pathways of complement activation are required for 
survival of WNV infection. Wild-type (n = 95), C1q−/− (n = 60), C4−/− 
(n = 34), fD−/− (n = 57), fB−/− (n = 50), and C5aR−/− (n = 50) C57BL/6 
mice were infected with 102 PFU by footpad injection in at least three 
independent experiments. Signifi  cant decreases in survival as compared 
with wild-type mice were noted for all complement defi  cient mice 
(P ≤ 0.0004), except C5aR−/− mice (P = 0.5).
Figure 3.  WNV infection in serum and lymphoid tissues. WNV RNA 
levels in the serum (A), spleen (C), and draining inguinal lymph node (D) 
of wild-type, C1q−/−, C4−/−, fD−/−, and fB−/− mice at the indicated days 
were determined by quantitative RT-PCR from at least 4–6 independent 
mice per time point per group. Infectious WNV burden in the spleen (B) of 
wild-type, C1q−/−, C4−/−, fD−/−, and fB−/− mice at the indicated days was 
determined by plaque assay of samples from 8–15 mice per time point 
per group. The dotted line indicates the limit of sensitivity of the assay. 
Asterisks indicate time points at which differences are statistically signifi  -
cant compared with wild type.1374  COMPLEMENT PATHWAY CONTROL OF WNV INFECTION | Mehlhop and Diamond
the C1q−/− and C4−/− animals, viral burden in the inguinal 
lymph nodes was measured by quantitative RT-PCR (Fig. 3 D). 
Equivalent levels of WNV RNA were detected on the fi  rst 
and second days after infection in wild-type, C1q−/−, and 
C4−/− mice (P ≥ 0.8). However, by 3 d after infection four-
fold less WNV RNA was found in the draining inguinal 
lymph nodes of C1q (P = 0.05) and C4−/− mice (P = 0.04) 
compared with wild-type mice.
CNS: spinal cord. Distinct patterns of WNV invasion and 
accumulation in the spinal cord were observed in C1q−/−, 
C4−/−, fD−/−, and fB−/− mice (Fig. 4 A). In agreement with 
published studies, WNV was not detected in spinal cord sam-
ples from wild-type mice until day 8 after infection (16). 
Similarly, infectious virus was not recovered from the spinal 
cords of C1q−/− or fD−/− mice until day 8 after infection. 
In the absence of either fB or C4, however, WNV was de-
tected in a subset of spinal cord samples 2 d earlier. At day 6, 
47% (7 of 15) fB−/− and 50% (6 of 12) of C4−/− mice had 
measurable infectious WNV in the spinal cord (P ≤ 0.03). 
Overall, all complement-defi   cient mice had signifi  cantly 
higher peak spinal cord viral burdens by day 10 after infection 
compared with wild-type mice (P ≤ 0.03). Additionally, 
whereas 100% of complement-defi   cient mice exhibited 
WNV invasion of the spinal cord by day 10 after infection, 
only 73% (11 of 15) of wild-type mice had infectious WNV 
in the spinal cord at this time point. These results suggest that 
the diff  erent complement activation pathways modulate the 
entry and accumulation of WNV in the spinal cord.
CNS: brain. A slightly diff  erent pattern of infection was 
observed in the brain, as earlier viral invasion was observed in 
all complement-defi  cient mice (Fig. 4 C). Infectious virus 
was not recovered from the brains of wild-type adult mice 
until day 6, results that agree with our previous studies (16). 
In contrast, infectious virus was detected at day 4 in the brains 
of 33% of C4−/− (4 of 12), 18% of C1q−/− (2 of 11), 67% of 
fD−/− (8 of 12), and 60% of fB−/− (6 of 10) mice. On aver-
age, fD−/− mice had  30-fold higher levels of WNV in the 
brain than C1q−/− mice on day 4 after infection (P = 0.02). 
Viral burden in the brain peaked in wild-type mice on day 8 
after infection. In contrast, levels of infectious WNV con-
tinued to rise in C1q−/−, C4−/−, fD−/−, and fB−/− mice such 
that 10–200-fold higher levels were observed by day 10 after 
infection (P ≤ 0.04). The analysis of viral burden in the CNS 
suggests that a defi  ciency in primarily the alternative pathway 
results in earlier WNV entry and accumulation, whereas a 
defi  ciency in any of the complement pathways results in in-
creased viral load.
Pattern of WNV CNS infection
To evaluate if enhanced CNS WNV infection was the result 
of a change in viral tropism, we examined brain and spinal 
cord sections for WNV antigen (Fig. 5 and unpublished data). 
WNV antigen localized to cells that stained positive for neu-
ronal antigens (unpublished data) throughout the brain and 
spinal cord, in agreement with previous studies (16). Intense 
antigen staining in complement-defi  cient mice was observed 
in neurons of the cerebellum, brain stem, brain base, and 
cortex. Less intense antigen staining in CNS tissues was noted 
in wild-type mice, with sporadic infection of similar neuro-
nal populations. Thus, more neurons throughout the brain 
and spinal cord were infected at higher levels in the absence 
of complement activation compared with wild-type animals.
Virus-specifi  c antibody responses 
in complement-defi  cient mice
Because the production of anti-WNV antibody was depressed 
in C3−/− mice (20), we assessed the kinetics of specifi  c anti-
viral IgM and IgG production in C1q−/−, C4−/−, fD−/−, and 
fB−/− mice. Consistent with previous studies (14–16), in 
wild-type mice WNV-specifi  c IgM was detected by day 4 
after infection (Fig. 6 A), and WNV-specifi  c IgG was de-
tected by day 6 after infection (Fig. 6 B). Near normal devel-
opment of anti-WNV IgG and IgM was observed in the 
absence of alternative pathway activation in fD−/− and fB−/− 
mice (P ≥ 0.1). Additionally, in fB−/− mice, we observed no 
signifi  cant diff  erence in the isotype specifi  city (Fig. 6 C) or 
neutralizing activity of the WNV antibody response (Fig. 6 D). 
In contrast, the development of WNV-specifi  c IgG was 
Figure 4.  WNV infection in CNS tissues. Infectious WNV burden in 
(A) spinal cord and (C) brain from wild-type, C1q−/−, C4−/−, fD−/−, and fB−/− 
mice was determined by plaque assay of samples from 8–15 mice per time 
point per group. Scatter plots of (B) spinal cord and (D) brain titers from 
individual mice at day 4 or 10 are shown to the right of each graph. The limit 
of sensitivity of the assay and statistical signifi  cance are as described in Fig 3.JEM VOL. 203, May 15, 2006  1375
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  delayed in C1q−/− and C4−/− mice, with three- to fourfold 
reduced titers on day 8 after infection, respectively (P ≤ 
0.0003). However, this defi  cit disappeared by day 10, as nor-
mal levels of anti-WNV IgG were subsequently observed 
(P ≥ 0.5). Throughout the time course the anti-WNV IgM 
response was reduced only in the absence of C4 (P ≤ 0.03). 
Collectively, our serologic data establish that the IgM re-
sponse to WNV is C4 dependent, yet C1q, fD, and fB inde-
pendent, suggesting a possible role for the lectin pathway. 
Consistent with this, C1q−/− × fD−/− mice had normal anti-
WNV IgM and IgG responses on day 10 after infection 
  (unpublished data; P = 0.7).
T cell response in C4−/−, C1q−/−, fD−/−, and fB−/− mice
CD8+ T cells are required for clearance of WNV from the 
CNS (16, 17). Studies with infl  uenza and lymphocytic cho-
riomeningits virus (LCMV) have found that virus-specifi  c T 
cell priming is inhibited in the absence of C3 (4, 27). Because 
enhanced WNV accumulation in the CNS is observed in all 
complement-defi  cient mice, we examined how the individ-
ual complement pathway defi  ciencies aff  ected the response of 
CD8+ T cells to WNV infection (Fig. 7 A). We evaluated 
intracellular IFNγ expression in splenocytes from mock- and 
WNV-infected C1q−/−, C4−/−, fD−/−, and fB−/− mice. 
By day 8 after infection, there was a  2.5-fold increase in the 
total number of splenic CD4+ and CD8+ cells that expressed 
IFNγ in both wild-type (P = 0.0007) and C1q−/− mice 
(P  = 0.03). This increase in IFNγ expression was not 
observed in CD4+ or CD8+ splenocytes from WNV-infected 
C4−/−, fD−/−, or fB−/− mice. Thus, our data suggests that C4 
and the alternative pathway of complement activation both are 
required for full T cell responsiveness after WNV infection.
T cell traffi  cking to WNV-infected CNS
Traffi   cking of eff  ector T cells into WNV-infected CNS tis-
sues requires cellular activation and up-regulation of select 
chemokine receptors (28). As an independent measure of the 
T cell activity, we tested which pathway of complement ac-
tivation was required for T cell migration into the CNS of 
WNV-infected animals. We isolated brain-infi  ltrating leu-
kocytes on day 9 after infection in wild-type, C4−/−, 
C1q−/−, and fB−/− mice and quantifi  ed T cells by fl  ow cy-
tometry (Fig. 7 C). We isolated an average of 2.3 ± 0.5 × 
104 CD3+CD4+ T cells and 4.2 ± 0.6 × 104 CD3+CD8+ 
T cells from the brains (n = 18) of wild-type mice. Consis-
tent with our IFNγ expression data, the numbers of infi  ltrat-
ing CD4+ and CD8+ T cells were reduced signifi  cantly in 
Figure 5.  WNV antigen staining in the brain. The brains of wild-
type, C1q−/−, C4−/−, and fD−/− mice were harvested on day 10, sectioned, 
and stained for WNV. Representative images of the cerebellum, cortex, 
and brain stem were determined after staining three to four mice per 
group. Bar, 200 μm.
Figure 6.  Humoral responses against WNV. Serum samples from 
wild-type, C1q−/−, C4−/−, fD−/−, and fB−/− mice were collected at the 
indicated time points. Titers of specifi  c IgM (A) and IgG (B) against 
WNV were calculated after incubating serum samples with absorbed 
control or WNV E proteins. The isotype of WNV-specifi  c IgG responses 
(C) was analyzed on day 8 after infection. Neutralizing activity (D) of 
serum samples from wild-type and fB−/− mice on day 8 after infection 
was determined by a fl  ow cytometry–based neutralization assay. Data 
are an average of at least three independent experiments performed 
in duplicate and refl  ect 5–10 mice per group. Asterisks indicate time 
points at which differences are statistically signifi  cant compared with 
wild type (P < 0.05).1376  COMPLEMENT PATHWAY CONTROL OF WNV INFECTION | Mehlhop and Diamond
the absence of either fB or C4 (n ≥ 12, P ≤ 0.04). No dif-
ference in CNS T cell migration was observed in the   absence 
of C1q in either the CD4+ or CD8+ compartment (n = 15, 
P ≥ 0.3). Collectively, our data suggests that the lectin and 
alternative pathways of complement activation are required 
for normal T cell responsiveness and CNS traffi   cking after 
WNV infection.
DISCUSSION
In this study, we report that diff  erent pathways of comple-
ment activation can exert independent protective eff  ects in 
response to viral infection (Table I). WNV infection activates 
the complement system in vivo, and all three complement 
activation pathways are required for protection against WNV. 
However, diff  erences in priming of adaptive immune re-
sponses to WNV were observed in mice lacking individual 
components of all three pathways of complement activation. 
Defi  ciencies in the alternative pathway were associated with 
slightly delayed splenic clearance, blunted T cell responses, 
yet near normal anti-WNV antibody profi  les. Defi  ciencies in 
classical and lectin pathway activation were associated with 
decreased splenic infection and signifi  cant defi  cits in both B 
and T cell responses against WNV. A defi  ciency in the classi-
cal pathway alone was associated with markedly decreased 
splenic infection, yet normal T cell responses and near nor-
mal antibody responses. Importantly, not all defects in the 
complement system predispose mice to enhanced WNV sus-
ceptibility, as mice lacking the C5aR exhibited no increase in 
mortality after infection. This latter result was not unexpected 
as C5aR activity primarily modulates granulocyte responses, 
a cell type that has not been implicated in the pathogenesis or 
immune response to WNV infection (29).
All pathways of complement activation are required 
to control WNV infection
Although clinical studies have suggested that increased com-
plement activation may be associated with more severe forms 
of infection with two related viruses of the Flaviviridae family, 
Figure 7.  T cell activation and traffi  cking after WNV infection. 
(A) Mock or WNV-infected splenocytes from wild-type, C1q−/−, C4−/−, 
fD−/−, and fB−/− mice on day 8 were harvested and stimulated ex vivo. 
Cells were stained for CD4 or CD8 and intracellular IFNγ and analyzed by 
fl  ow cytometry. Data are an average of at least three independent experi-
ments and refl  ect 6–10 mice per group. Asterisks indicate differences 
from mock infected that are statistically signifi  cant (*P < 0.05; **P < 
0.005). (B) Representative fl  ow cytometry profi  les showing intracellular 
IFNγ staining of splenic CD8+ T cells after WNV infection in wild-type or 
complement-defi  cient mice. The percentage of double-positive cells is 
indicated in the top right corner. (C) Brains were harvested from WNV-
infected wild-type, C1q−/−, C4−/−, and fB−/− mice on day 9. Leukocytes 
were isolated by percoll gradient centrifugation and double-stained for 
CD3 and CD4 or CD8. The total number of brain infi  ltrating CD4+ or CD8+ 
T cells was determined by multiplying the total number of leukocytes 
from three pooled brains by the percentage of double-positive cells as 
measured by fl  ow cytometry. Data are an average of at least three inde-
pendent experiments and refl  ect at least fi  ve groups of three mice. Aster-
isks indicate differences from wild type that are statistically signifi  cant 
(*P < 0.05; **P < 0.005). (D) Representative fl  ow cytometry profi  les 
showing CD3+CD8+ T cells in the brain after WNV infection in wild-type 
or complement-defi  cient mice.JEM VOL. 203, May 15, 2006  1377
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dengue virus (21) and hepatitis C virus (30), C3 was essential 
for controlling WNV infection (20). Although the studies in 
C3−/− mice were consistent with models of complement-
  dependent control of other viral infections including HSV, 
infl  uenza, and LCMV (2–4, 31, 32), no investigation had sys-
tematically addressed how the diff  erent activation pathways 
coordinate protection. Our experiments demonstrate that all 
complement activation pathways are required for control of 
severe WNV disease. The virologic experiments suggest that 
complement limits viral spread and facilitates clearance of 
WNV within the CNS. As many complement proteins are 
constitutively expressed within the CNS (33) and up-regulated 
after infection with other neurotropic viruses (34–36), com-
plement activation in the CNS could be critical for destr  uction 
of viral particles or virus-infected neuronal cells. Alternatively, 
the defects observed in priming adaptive immune responses to 
WNV in complement-defi  cient mice (see below) may result in 
earlier spread and/or decreased clearance.
Most complement-defi   cient mice had near wild-type 
levels of viral RNA in serum throughout the time course, 
suggesting that the dominant antiviral role of complement 
activation may not be direct virolysis. Because IgM fi  xes 
complement by the classical pathway and WNV particles can 
be neutralized effi   ciently in vitro by exogenous rabbit com-
plement (20), we anticipated increased viremia in C1q−/− 
and C4−/− mice. However, we only observed a transient in-
crease in viremia in C4−/− mice, which may be secondary to 
depressed levels of antiviral IgM in these mice. Viral clear-
ance from serum is known to correlate with the induction of 
WNV-specifi  c IgM at days 4 and 6 after infection (15). The 
relatively low viral neutralizing activity of serum comple-
ment in mice may be caused by the reduced function of the 
mouse classical pathway C5 convertase (37, 38). Our prior in 
vivo experiments support this, as antibody-mediated protec-
tion from WNV disease was not signifi  cantly attenuated in 
C1q−/− or C4−/− mice (39).
Although the magnitude and kinetics of viremia were 
roughly equivalent, earlier CNS viral invasion was observed 
in all complement-defi  cient mice. This early CNS seeding 
was most consistently observed in mice lacking fB or fD. Al-
though the mechanism remains unclear, alternative pathway 
activation during the initial phases of infection could induce 
infl  ammatory mediators that facilitate viral blood-brain barrier 
crossing. TNF-α generation in peripheral lymphoid tissues 
has been suggested to modulate blood-brain barrier permea-
bility and WNV neuroinvasion (40). Notably, genetic disrup-
tion or antibody blockade of alternative pathway activation or 
CR3 function signifi  cantly inhibited TNF-α secretion from 
human or murine leukocytes after exposure to group B Strep-
tococcus (41). Experiments that examine the relationship be-
tween CNS viral entry and cytokine profi  les  after  WNV 
infection in complement-suffi   cient and -defi  cient mice may 
elucidate the molecular basis for this stage in pathogenesis.
Classical pathway activation facilitates secondary lymphoid 
organ WNV infection
A surprising result was the requirement of C1q and C4 for 
normal levels of WNV infection in the spleen and draining 
lymph node. In the absence of C1q, infectious virus was not 
detected in the spleen, and 100,000-fold less WNV RNA 
was measured on day 6 after infection. Additionally, WNV 
infection of the draining inguinal lymph nodes was reduced 
in the absence of C1q beginning on day 3 after infection. In 
the absence of C4, fewer spleen samples contained less infec-
tious virus than those of wild-type animals, and less WNV 
RNA was detected in the spleen and draining inguinal lymph 
node. At fi  rst glance, this observation appears consistent with 
earlier in vitro studies that showed complement and antiviral 
IgM enhanced WNV infection in macrophages (42, 43). Al-
though these studies suggested that IgM-dependent fi  xation 
of C3 split products (e.g., C3b, C3dg, or iC3b) on WNV 
enhanced infection, our prior studies with secreted IgM−/− 
or C3−/− mice showed normal WNV splenic infection (15, 
20). Based on this, we speculate that C1q directly or indi-
rectly interacts with WNV to facilitate splenic infection. 
  Direct C1q interaction with viral glycoproteins has been
observed for HIV-1, human T cell lymphotropic virus-1, 
and Moloney murine leukemia virus (6), and C1q-depen-
dent enhancement of infection has been demonstrated in 
  vitro for both HIV-1 and Ebola viruses (44, 45). Our data 
clearly establishes that WNV infection in the spleen does not 
signifi  cantly contribute to viremia or CNS seeding. Some-
what paradoxically, decreased productive splenic infection 
did not dramatically alter the induction of primary antiviral B 
Table I.  Summary of phenotypes observed during WNV infection of complement-defi  cient mice
Viremia Spleen CNS IgM IgG T cell activity Survival
WT ++++++ 65%
C4−/− D4 + + −+ +− D8 −− 0%
C1q−/− + None ++ + D8 −+17%
fB−/− + D6 ++ ++ + + − 4%
fD−/− + D6 ++ ++ + + ND 26%
C1q × fD−/− ND ND ND D10 + D10 + ND 10%
Viremia, infectious burden in the spleen and CNS, virus-specifi  c IgM and IgG responses, and T cell activity after WNV infection of wild-type, C4−/−, C1q−/−, fB−/−, fD−/−, and 
C1q × fD−/− mice are summarized above. Differences from WNV infection in wild-type mice (+) at specifi  c days after infection are indicated. Comparative levels are 
indicated by – (low), + (normal), or ++ (high). ND indicates experiments were not performed.1378  COMPLEMENT PATHWAY CONTROL OF WNV INFECTION | Mehlhop and Diamond
and T cell immune responses to WNV. This apparently con-
trasts with studies which show that follicular localization in 
the spleen is complement dependent and required for the 
development of antibody responses to soluble antigen (46) 
and vesicular stomatitis virus (2). For WNV, we hypothesize 
that T and B cell priming may occur in other secondary 
lymphoid tissues. Alternatively, despite an absence of pro-
ductive viral infection in the spleen, suffi   cient complement-
dependent antigen trapping occurs for antigen presentation 
and priming of antiviral adaptive immune responses.
Complement activation pathways and the humoral response
Combined with previous work, our current experiments indi-
cate that the development of a protective anti-WNV antibody 
response, in part, requires C3, C4, and CR1/2 (20). Because 
near normal anti-WNV antibody responses were observed in 
fB−/− or fD−/− mice, activation of the alternative pathway is 
not required for priming the antibody response against WNV. 
Our results are consistent with studies which demonstrate that 
fB−/− mice exhibit normal B cell priming to T cell–indepen-
dent and T cell–dependent antigens (47). We observed a tran-
sient delay in the development of antiviral IgG but not IgM in 
the absence of C1q, consistent with previous reports of defects 
in primary T cell–dependent IgG but not IgM responses in 
C1q−/− mice (46). Our data suggests the contribution of the 
classical pathway to anti-WNV antibody priming is relatively 
minor and could be secondary to the defect observed in splenic 
infection. The most severe defect in anti-WNV antibody de-
velopment was observed in the absence of C4, where IgM re-
sponses were blunted and IgG responses were delayed. Since 
the C1q−/− mice exhibited normal IgM responses, the C4-
dependent lectin pathway could play an important role in 
priming the antiviral IgM against WNV. Although no study 
has directly evaluated the contribution of the lectin pathway 
to antiviral antibody responses, this idea is consistent with 
work on HSV in which both the primary and memory antivi-
ral humoral responses were blunted in C4−/− mice (3, 48). 
Defects in MBL function and lectin pathway activation have 
been suggested to predispose individuals to HIV-1 (49), HSV-
2 (7), severe acute respiratory syndrome (50), and chronic 
hepatitis B infection (51). We speculate that the lectin path-
way may have an essential role in the priming of humoral 
  responses against some pathogens.
Complement activation pathways and T cell activation
An emerging literature has suggested an essential role for 
complement in priming antiviral T cell immunity. T cell re-
sponses to infl  uenza and LCMV require C3 activation (4, 
27), possibly by enhancing antigen uptake and presentation 
or T cell traffi   cking to infected organs. Effi   cient CD8+ CTL 
responses are critical for development of WNV immunity 
(16, 17), and complement-defi  cient mice with the greatest 
mortality (i.e., C4−/− and fB−/−) had associated T cell activa-
tion and traffi   cking defi  cits. Because previous studies with 
soluble antigens suggested that C1q-mediated immune com-
plex trapping contributed to T cell priming (46, 52), we 
  expected C1q−/− mice to have T cell defi  cits; however, this 
was not observed. We speculate that WNV antigen uptake 
and presentation may be reduced in the absence of lectin 
pathway activity and/or C4b deposition. Lectin pathway rec-
ognition induces opsonization of infl  uenza virus, HSV-2, and 
HIV-1 (53), and C4b deposition and CR1 binding can acti-
vate and enhance antigen presentation in human cells (54). 
Nonetheless, the defects in antiviral T cell responses in C4−/− 
mice could be indirect and attributed to the depressed anti-
WNV IgM responses and decreased immune complex clear-
ance. Although more experiments are necessary to identify 
the exact mechanism, our study is novel as it describes a role 
for C4 in T cell function after viral infection.
We also observed a requirement for the alternative path-
way in the development of T cell responses after WNV in-
fection. Because others have demonstrated an 80% reduction 
in classical pathway-dependent membrane attack complex 
formation in the absence of alternative pathway activity (55, 
56), WNV antigen presentation may be reduced in the ab-
sence of fB because of a failure to amplify classical and/or 
lectin pathway-initiated responses. This may attenuate C3b-
directed targeting, uptake, and presentation of WNV in lym-
phoid tissues (2, 4, 27). Alternatively, C3b engagement of 
CR3 may promote an appropriate cytokine environment for 
antiviral T cell priming: production of IFNγ and IL-12 were 
reduced by treatment of human monocytes with CR3 block-
ing antibodies or natural CR3 ligands (57).
Complement activation plays a critical role in innate rec-
ognition and neutralization of pathogens in vivo (3, 4, 58). 
Our study expands the current knowledge of the in vivo 
mechanisms of complement-mediated antiviral immunity, 
and in particular suggests that activation of complement by 
distinct pathways may control pathogens by triggering diff  er-
ent eff  ector arms of antiviral immunity. A limitation of our 
study is that it does not address the precise mechanism by 
which the three complement activation pathways stimulate 
diff  erent adaptive immune responses; the diff  erences could be 
because of quantitative or qualitative variation in the genera-
tion of C3 or C5 activation fragments. Regardless, a fully 
functional complement cascade is clearly important for con-
trolling and clearing WNV given that antibody and CD8+ 
T cells both are essential for protection (14, 16, 17). It is in-
triguing to consider that severe WNV infection in humans, 
which occurs infrequently ( 1/150), could be more com-
mon in patients with dysfunctional complement responses. 
Although complete defi  ciencies of complement proteins are 
rare, heterozygous defi  ciencies of C4 and MBL are common 
(59) and have been associated with an increased risk of viral 
diseases (30, 49, 51, 60). As therapies against WNV become 
available, it will be important to target high-risk populations. 
Depressed levels of complement proteins or reduced comple-
ment activity could explain why some seemingly healthy pa-
tients develop severe disease after WNV infection. Genetic 
studies that evaluate the risk factors of neuroinvasive WNV 
infection in humans should include an analysis of common 
complement gene allelic polymorphisms.JEM VOL. 203, May 15, 2006  1379
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MATERIALS AND METHODS
Viruses and cells. The WNV strain 3000.0259 was isolated in New York 
in 2000 and used for all studies (61). All mouse experiments used a low pas-
sage stock (P = 2) that was propagated once in C6/36 Aedes albopictus cells.
Mice. C4−/− (62), C1q−/− (63), fD−/− (24), C1q × fD−/−, fB−/− (47), and 
C5aR−/− (64) mice on a pure C57BL/6 (H-2b) background and were ob-
tained from colleagues (C. Gerard, Harvard Medical School, Boston, MA; 
M. Botto, Imperial College, London, UK; M. Carroll, Harvard Medical 
School, Boston, MA; G. Stahl, Harvard Medical School, Boston, MA; and 
H. Molina, Washington University School of Medicine). The congenic 
wild-type C57BL/6 control mice were purchased commercially (Jackson 
Laboratories). All mice were housed in the pathogen-free BSL3 mouse facil-
ity at Washington University School of Medicine. Studies were performed 
in compliance with the guidelines of the Washington University School of 
Medicine Animal Safety Committee. 8–12-wk-old mice were inoculated 
subcutaneously via footpad injection with 102 PFUs diluted in Hanks bal-
anced salt solution and 1% heat inactivated FBS.
Complement hemolysis assays. Levels of functional mouse C4 were 
  determined by an erythrocyte hemolysis assay as previously described (23). 
In brief, sheep erythrocytes (Colorado Serum Co.) were coated with rabbit 
anti–sheep erythrocyte IgG (Rockland Immunochemical) at 37°C for 30 min. 
After extensive washing, antibody-coated sheep erythrocytes (5 × 106) were 
mixed with C4-depleted guinea pig serum (Complement Technologies, 
Inc.) and serial dilutions of mouse serum from naive or WNV-infected 
C57BL/6 mice. Reactions were incubated at 37°C for 1 h and stopped by 
the addition of 1 vol of PBS at 0°C. Erythrocytes were pelleted, supernatants 
were removed, and lysis was measured by using a 96-well plate reader at an 
OD405. Levels of C3 were determined as above using C3-depleted normal 
human serum (Complement Technologies). The 50% value of hemolytic 
complement activity (CH50) was determined as described previously (65).
C3 Western blotting. Complement activation was assessed by Western 
blot as previously described (24). Serum samples were collected from naive 
or WNV-infected C57BL/6 mice on day 2 after infection, diluted in PBS, 
boiled in SDS reducing sample buff  er, and subjected to SDS PAGE using a 
4–20% gradient gel. After transfer to a PVDF membrane, C3 and its cleavage 
products were detected with goat anti–mouse C3 IgG (MP Biomedicals) 
followed by horseradish peroxidase–conjugated donkey anti–goat IgG 
F(ab)′2 (Jackson ImmunoResearch). C3 bands were visualized using the 
ECL Plus chemiluminescent substrate system (BD Biosciences).
Quantifi  cation of viral burden. For analysis of viral burden, organs were 
recovered at days 2, 4, 6, 8, and 10 postinfection after cardiac perfusion with 
10 ml of PBS. Tissues were weighed, homogenized using a Bead-beater 
  apparatus, and titrated for WNV by plaque assay on BHK21-15 cells as 
  described previously (14). Serum was obtained from whole blood by phle-
botomy of the axillary vein immediately before sacrifi  ce. Viral RNA was 
prepared from serum by using a Qia-Amp viral RNA recovery kit (Qiagen) 
and quantifi  ed by real-time fl  uorogenic RT-PCR on an ABI 7000 sequence 
detection system (Applied Biosystems) using primers and probes correspond-
ing to a segment of the E gene as described previously (25). Viral RNA 
was  extracted from lymph node and spleen tissue homogenates using 
the RNeasy isolation kit (Qiagen) and quantifi  ed by fl  uorogenic RT-PCR 
as   described above. Values were normalized to the level of 18S RNA as 
determined by fl  uorogenic RT-PCR with a commercially available kit 
(Applied Biosystems).
Serologic analysis. WNV-specifi  c IgM and IgG levels were determined 
by an envelope (E) protein–specifi  c ELISA, as described previously (14). In 
brief, a soluble WNV E-protein with a COOH-terminal hexa-histidine 
(His6) tag was purifi  ed from baculovirus-infected Hi5 insect cells by nickel-
affi   nity chromatography (39) and used to coat Maxi-Sorp microtiter plates 
(Nalgene Nunc) overnight at 4°C. After blocking with PBS 1% BSA, 3% 
horse serum, 0.05% Tween-20, and 0.025% NaN3, plates were incubated 
with fourfold serial dilutions of heat-inactivated serum samples overnight 
at 4°C. Plates were washed, incubated with biotin-conjugated goat anti–
mouse IgM, IgG, IgG1, IgG2a, IgG2c, or IgG3 (Southern Biotech), followed 
by strepatavidin-HRP (Invitrogen), and developed with tetramethylbenzi-
dine substrate (Dako). The OD450 was determined, and the adjusted OD 
was determined by subtracting the OD450 value for each sample on blocked 
control wells. Titers represent the serum dilution yielding an adjusted 
OD450 value equivalent to three standard deviations above the background 
of the assay.
The neutralizing activity of the WNV-specifi  c antibody response was 
determined using a previously described high-throughput fl  ow cytometry–
based neutralization assay with WNV virus-like particles that express a re-
porter gene (green fl  uorescent protein [GFP]) (66). WNV virus-like particles 
were incubated with serial dilutions of heat-inactivated serum samples before 
incubation with permissive Raji cells expressing DC-SIGN-R (67). 2 d 
later, cells were fi  xed in 1% paraformaldehyde, analyzed by fl  ow cytometry 
for GFP expression, and the titer of 50% inhibition (EC50) was determined 
using GraphPad Prism software.
Immunohistochemistry. Brain and spinal cord were harvested from 
infected mice on day 10 postinfection after perfusion with 20 ml of PBS. 
Tissues were fi  xed in 4% paraformaldehyde in PBS for 24 h at 4°C, then 
embedded in paraffi   n, sectioned, and stained for WNV infection using mAbs 
(E18, E22, and E33) against the WNV E protein (18), after an antigen re-
trieval step (Dako Cytomation). Staining was detected after incubation with 
streptavidin-conjugated horseradish peroxidase and development with di-
aminobenzidine. Slides were counterstained with hematoxylin to facilitate 
visualization of tissue histology.
Intracellular IFN-𝗄 staining. Intracellular IFN-γ staining of wild-type 
and complement-defi  cient splenocytes was performed as described previ-
ously (19). In brief, at day 8 after infection, splenocytes were harvested from 
wild-type and C1q−/−, fD−/−, fB−/−, or C4−/− mice. Erythrocytes were 
lysed with ACK lysis buff  er (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM 
Na2EDTA) and splenocytes were counted. In a 96-well plate, 106 spleno-
cytes were stimulated with 50 ng/ml PMA (Sigma-Aldrich) and 1 μM Iono-
mycin (Sigma-Aldrich) in the presence of Golgi plug (BD PharMingen) for 
4 h at 37°C. Cells were harvested and stained with either FITC-conjugated 
anti-CD4 (L3T4) or anti-CD8α (Ly-2) antibody (BD PharMingen). Cells 
were then washed and fi  xed in 4% paraformaldehyde, permeabilized with 
0.5% saponin, and stained with AlexaFluor 647–conjugated rat anti–mouse 
IFN-γ antibody or rat IgG1 isotype control (BD PharMingen), and analyzed 
by fl  ow cytometry. The total numbers of IFNγ-expressing CD8+ cells was 
determined by multiplying the percentage of IFNγ+ CD8+ cells by the total 
numbers of splenocytes harvested.
Brain T cell isolation. Brain infi  ltrating CD4+ and CD8+ T cells were 
isolated and quantifi  ed as previously described (68). Complement-defi  cient 
and wild-type mice were anaesthetized and perfused with 20 ml of PBS on 
day 9 after infection with 102 PFU of WNV. Individual brains were har-
vested into RPMI supplemented with 5% FBS and homogenized by pressing 
through a 70-μm mesh tissue strainer (BD Biosciences). The cell homoge-
nates were centrifuged, and the cell pellets were resuspended in RPMI with 
5% FBS and overlaid on a 70–30% isotonic percoll (Pharmacia) step gradi-
ent. The gradients were centrifuged (800 g for 25 min at 25°C), and the leu-
kocytes were collected from between the 70 and 30% interface. Leukocytes 
from three brains were pooled, washed twice, and stained for CD4+ or 
CD8+ T cells with anti-CD3 (17A2) and anti-CD8α (Ly-2) or anti-CD4 
(L3T4) antibodies (BD PharMingen) in the presence of 5% goat serum after 
Fc block (2.4G2; BD PharMingen). After washing, cells were fi  xed with 1% 
paraformaldehyde in PBS and analyzed by FACscan (Becton Dickinson) 
with CellQuest software. The total numbers of CD4+ or CD8+ T cells from 
each brain were determined by multiplying the percentage of CD3+CD4+ 
or CD3+CD8+ cells by the total numbers of leukocytes harvested.1380  COMPLEMENT PATHWAY CONTROL OF WNV INFECTION | Mehlhop and Diamond
Data analysis. For survival analysis, Kaplan-Meier survival curves were 
plotted using Prism software (GraphPad) and analyzed by the log rank test. 
Statistical signifi  cance of complement levels, survival time, viral burdens, 
  antiviral antibody titers, and total number of activated T cells were analyzed 
by an unpaired t test or Mann-Whitney test.
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